Copy to clipboard 
Advita Ortho is ready to play offense, said CEO Aurelio Sahagun.
Advita launched in early November 2025 after a group of investors purchased the operations and assets of Exactech, which filed for bankruptcy after multiple FDA recalls and patient lawsuits. With deep financial backing, an established product portfolio, commitment to surgeon success and millions of dollars invested in quality control, Advita is on track for growth in the joint replacement market.
“We’re a global company. We’re well capitalized. We have relatively significant market share in different areas of the business, but we still consider ourselves a small company,” Mr. Sahagun said. “We want to act like a small company in terms of proximity to customers, quick decision-making, and being agile. This is going to be a competitive advantage for us.”
Who is Advita Ortho?
Advita was founded with investments from Strategic Value Partners, Stellex Capital Management, and Greywolf Capital Management, and is led by Mr. Sahagun and a board of directors with significant orthopedic experience, including Luigi Ferrari, Andrew Ekdahl, and Dave Demski.
The company seeks to strike a balance between its legacy of product innovation and its new dedication to integrity, reliability and its vision to be the most trusted partner for orthopedic surgeons, Mr. Sahagun said. He noted that the organization’s rate of change has been significant over the last four months. About 60% of the company’s leadership team has turned over since Advita was established, and quality control processes have been implemented across R&D and manufacturing. All while the company has maintained its global presence, with operations in 10 countries and sales in 30.
“The commitment now from leadership, myself and the team, is to get back to the level of growth that we had in the past,” Mr. Sahagun said. “The ambition and support are there.”
What Products do They Sell?
Advita acquired and distributes Exactech’s Equinoxe Shoulder, Vantage Ankle, Alteon Hip, Truliant Knee, Newton balancing technology and GPS navigation, and distributes the Spartan Hip and Triverse Knee lines.
The company’s Active Intelligence ecosystem of technologies, which includes GPS navigation, Newton, Predict+ and planning software, is already helping Advita compete in the market, Mr. Sahagun said. He noted that real-time intelligence and predictive analytics have the potential to change clinical decision-making, and Advita’s enabling and digital technology systems are cost-effective and workflow-friendly for surgeons and ASCs.
When the company considers how it wants to be recognized in the market, Mr. Sahagun pointed out Active Intelligence and GPS navigation. GPS can be used with Advita’s shoulder, ankle and knee implant systems, and has years of clinical data from more than 100,000 cases.
Since the start of the year, Advita Ortho has launched and performed surgeries with its next-generation GPS Shoulder System; introduced its AI One platform, which uses intraoperative data to analyze surgical performance and workflow; and expanded its Chime Platform to include AI-powered capabilities designed to support secure clinical collaboration and peer-to-peer knowledge exchange among surgeons.
Advita’s leadership believes the company’s strongest organic growth will continue to come from its extremities portfolio and said it will consider tuck-in acquisitions to bolster its product line.
Mr. Sahagun also noted that Advita’s knee and hip replacement implants need updates to better align with surgeon preferences in certain geographies, and that the company is committed to growing its market share through a strong cadence of new product introductions.
“I feel very confident about the pipeline of products that we’re bringing to the market,” he said. “We’re going back to being first to market in many different areas.”
What are Advita’s Near-term Priorities?
Advita’s leadership team is building a company that they hope will surpass Exactech’s nearly 40-year legacy.
The company’s current priorities include delivering consistent, reliable growth and strengthening surgeon performance; expanding its Active Intelligence ecosystems; investing in quality and manufacturing excellence; advancing its clinical research and data that support its implant and digital technology portfolio; and building the culture and talent that will propel the company through its first decade of life.
While those are important priorities in establishing a foundation for the young company, Mr. Sahagun said that Advita must also respond to the market forces at play in joint replacement. He pointed to three market trends he’s closely watching and expects Advita to respond to.
First is the rapid acceleration of AI and machine learning, and the shift toward personalized, data-driven care. Second is the shift of procedures from the hospital to the ASC setting, along with the surgeon’s interest in efficient implants and technology portfolios. Third is the focus on value in healthcare, driving better outcomes, reducing variability and investing in technology that supports surgical efficiency without increasing burden in and outside of the operating room.
Mr. Sahagun said Advita is doubling down on driving growth and expects the company to be a strong challenger in numerous markets.
“What hasn’t changed is the ambition that we have as a company,” Mr. Sahagun said. “We really want to get out there and get back to the level of growth this company historically was used to.”
Advita Ortho is ready to play offense, said CEO Aurelio Sahagun.
Advita launched in early November 2025 after a group of investors purchased the operations and assets of Exactech, which filed for bankruptcy after multiple FDA recalls and patient lawsuits. With deep financial backing, an established product portfolio, commitment to surgeon...
Advita Ortho is ready to play offense, said CEO Aurelio Sahagun.
Advita launched in early November 2025 after a group of investors purchased the operations and assets of Exactech, which filed for bankruptcy after multiple FDA recalls and patient lawsuits. With deep financial backing, an established product portfolio, commitment to surgeon success and millions of dollars invested in quality control, Advita is on track for growth in the joint replacement market.
“We’re a global company. We’re well capitalized. We have relatively significant market share in different areas of the business, but we still consider ourselves a small company,” Mr. Sahagun said. “We want to act like a small company in terms of proximity to customers, quick decision-making, and being agile. This is going to be a competitive advantage for us.”
Who is Advita Ortho?
Advita was founded with investments from Strategic Value Partners, Stellex Capital Management, and Greywolf Capital Management, and is led by Mr. Sahagun and a board of directors with significant orthopedic experience, including Luigi Ferrari, Andrew Ekdahl, and Dave Demski.
The company seeks to strike a balance between its legacy of product innovation and its new dedication to integrity, reliability and its vision to be the most trusted partner for orthopedic surgeons, Mr. Sahagun said. He noted that the organization’s rate of change has been significant over the last four months. About 60% of the company’s leadership team has turned over since Advita was established, and quality control processes have been implemented across R&D and manufacturing. All while the company has maintained its global presence, with operations in 10 countries and sales in 30.
“The commitment now from leadership, myself and the team, is to get back to the level of growth that we had in the past,” Mr. Sahagun said. “The ambition and support are there.”
What Products do They Sell?
Advita acquired and distributes Exactech’s Equinoxe Shoulder, Vantage Ankle, Alteon Hip, Truliant Knee, Newton balancing technology and GPS navigation, and distributes the Spartan Hip and Triverse Knee lines.
The company’s Active Intelligence ecosystem of technologies, which includes GPS navigation, Newton, Predict+ and planning software, is already helping Advita compete in the market, Mr. Sahagun said. He noted that real-time intelligence and predictive analytics have the potential to change clinical decision-making, and Advita’s enabling and digital technology systems are cost-effective and workflow-friendly for surgeons and ASCs.
When the company considers how it wants to be recognized in the market, Mr. Sahagun pointed out Active Intelligence and GPS navigation. GPS can be used with Advita’s shoulder, ankle and knee implant systems, and has years of clinical data from more than 100,000 cases.
Since the start of the year, Advita Ortho has launched and performed surgeries with its next-generation GPS Shoulder System; introduced its AI One platform, which uses intraoperative data to analyze surgical performance and workflow; and expanded its Chime Platform to include AI-powered capabilities designed to support secure clinical collaboration and peer-to-peer knowledge exchange among surgeons.
Advita’s leadership believes the company’s strongest organic growth will continue to come from its extremities portfolio and said it will consider tuck-in acquisitions to bolster its product line.
Mr. Sahagun also noted that Advita’s knee and hip replacement implants need updates to better align with surgeon preferences in certain geographies, and that the company is committed to growing its market share through a strong cadence of new product introductions.
“I feel very confident about the pipeline of products that we’re bringing to the market,” he said. “We’re going back to being first to market in many different areas.”
What are Advita’s Near-term Priorities?
Advita’s leadership team is building a company that they hope will surpass Exactech’s nearly 40-year legacy.
The company’s current priorities include delivering consistent, reliable growth and strengthening surgeon performance; expanding its Active Intelligence ecosystems; investing in quality and manufacturing excellence; advancing its clinical research and data that support its implant and digital technology portfolio; and building the culture and talent that will propel the company through its first decade of life.
While those are important priorities in establishing a foundation for the young company, Mr. Sahagun said that Advita must also respond to the market forces at play in joint replacement. He pointed to three market trends he’s closely watching and expects Advita to respond to.
First is the rapid acceleration of AI and machine learning, and the shift toward personalized, data-driven care. Second is the shift of procedures from the hospital to the ASC setting, along with the surgeon’s interest in efficient implants and technology portfolios. Third is the focus on value in healthcare, driving better outcomes, reducing variability and investing in technology that supports surgical efficiency without increasing burden in and outside of the operating room.
Mr. Sahagun said Advita is doubling down on driving growth and expects the company to be a strong challenger in numerous markets.
“What hasn’t changed is the ambition that we have as a company,” Mr. Sahagun said. “We really want to get out there and get back to the level of growth this company historically was used to.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
CL
Carolyn LaWell is ORTHOWORLD's Chief Content Officer. She joined ORTHOWORLD in 2012 to oversee its editorial and industry education. She previously served in editor roles at B2B magazines and newspapers.
